Emerging evidence suggests that the gut microbiome serves as a reservoir for antigens that may influence intratumoral immune activity and the response to immunotherapy. However, commensal heterogeneity and the dynamic nature of immune cells have challenged and limited mechanistic studies. To address this, Najar and colleagues developed a model referred to hereafter as B16-3340, an engineered mouse melanoma cell line expressing a TCR-activating protein fragment of segmented filamentous bacteria (SFB), a gut commensal microorganism. When specific pathogen–free mice were colonized with SFB prior to subcutaneous B16-3340 injection, the shared antigen, expressed by both bacteria and tumors, effectively primed T cells, sensitizing the tumors to immune checkpoint blockade (ICB) via anti–PD-1. Similar results were observed in engineered Lewis lung carcinoma and colon adenocarcinoma mouse models, suggesting that the SFB-mediated response to ICB may not be limited to melanoma. Functional depletion studies revealed that this phenotype depended on both CD4+ and CD8+ T cells and that CD4 depletion was sufficient to impair CD8+ T-cell effector function within the tumors of ICB-treated, SFB-colonized animals. Single-cell RNA sequencing analysis of CD4+ T cells in the small intestine lamina propria (SILP) of ICB-treated animals further characterized an SFB-dependent cluster of IL17A+ TH17 cells within the gut. Conversely, tumors from ICB-treated, SFB-colonized animals harbored a unique IFNγ+ TH1-like subset of CD4+ T cells that was not observed in SFB-naïve controls. TCR repertoire analysis, fate mapping, and adoptive transfer experiments consistently supported a link between these two cell populations, indicating that SFB-dependent IL17A+ TH17 cells in the SILP can both migrate and transdifferentiate to give rise to intratumoral TH1-like cells. In a diphtheria toxin–mediated Il17a-knockout model, B16-3340 tumors in SFB-colonized animals contained fewer antigen-specific IFNγ+CD4+ cells, exhibited diminished CD8+ effector function, and were less sensitive to ICB, further emphasizing a critical role for this population of TH17 cells in regulating antitumor immune activity. In summary, this study suggests that antigens in the gut microbiome may influence TH17 plasticity and recruitment to tumors with shared antigens and that this subset of CD4+ cells can remodel the immune landscape to modulate ICB efficacy.Najar TA, Hao Y, Hao Y, Romero-Meza G, Dolynuk A, Almo E, et al. Microbiota-induced T cell plasticity enables immune-mediated tumour control. Nature 2026 Jan 14 Epub ahead of print.Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at https://aacrjournals.org/cdnews.
A Mon, study studied this question.